Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders
Authors:
- 26 February 2011
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Therapeutic Targets
- Vol. 15 (5) , 557-577
Abstract
Introduction: Current drugs for the treatment of psychiatric or neurodegenerative disorders have limitations. Psychotherapeutic drugs such as typical and atypical antipsychotics, tricyclic antidepr...Keywords
This publication has 137 references indexed in Scilit:
- The sigma-1 receptor chaperone as an inter-organelle signaling modulatorTrends in Pharmacological Sciences, 2010
- The sigma-1 receptor is enriched in postsynaptic sites of C-terminals in mouse motoneurons. An anatomical and behavioral studyNeuroscience, 2010
- Synapse Pathology in Psychiatric and Neurologic DiseaseCurrent Neurology and Neuroscience Reports, 2010
- Dendritic vulnerability in neurodegenerative disease: insights from analyses of cortical pyramidal neurons in transgenic mouse modelsBrain Structure and Function, 2010
- The pharmacology of sigma-1 receptorsPharmacology & Therapeutics, 2009
- Molecular Mechanisms of Psychostimulant-induced Structural PlasticityPharmacopsychiatry, 2009
- Sigma-1 receptor knockout mice display a depressive-like phenotypeBehavioural Brain Research, 2009
- MAM: more than just a housekeeperTrends in Cell Biology, 2009
- Sigma receptors suppress multiple aspects of microglial activationGlia, 2008
- The σ-Receptor Antagonist BD-1063 Decreases Ethanol Intake and Reinforcement in Animal Models of Excessive DrinkingNeuropsychopharmacology, 2008